Here are the 424B prospectus supplements from VolitionRx Limited (VNRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VNRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VNRX filings page.
VolitionRx Limited is registering $1.55-priced equity: up to 2,960,000 shares of common stock with accompanying warrants to purchase up to 1,480,000 shares. The units are sold at a combined public offering price of $1.55 per share and accompanying warrant; each Warrant has an exercise price of $1.55 and a five-year term. The offering includes Pre-Funded Warrants for purchasers who would otherwise exceed 4.99% (or elect 9.99%) ownership, with an exercise price of $0.001 per Pre-Funded Warrant. Net proceeds are estimated at approximately $4.1 million assuming full exercise of Pre-Funded Warrants and no exercise of the Warrants; proceeds are intended for research, development, clinical studies, commercialization, working capital and partial repayment of specified convertible notes.
VolitionRx Limited (VNRX) is proposing a registered offering of common stock, detachable warrants and pre-funded warrants pursuant to a preliminary prospectus supplement to a shelf registration statement. The offering includes pre-funded warrants for purchasers who would exceed 4.99% (or elect 9.99%) ownership limits. The company disclosed a one-for-20 reverse stock split effective April 28, 2026, reported 8,627,191 shares outstanding as of May 26, 2026, and stated a public float of approximately $29.7 million under Form S-3 instruction I.B.6. Net proceeds are intended for research and development, clinical studies, commercialization, working capital and repayment of certain Lind Notes.